» Articles » PMID: 2553163

Recombinant Human Interleukin-3 and Granulocyte-macrophage Colony-stimulating Factor Show Common Biological Effects and Binding Characteristics on Human Monocytes

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1989 Nov 15
PMID 2553163
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Two human hemopoietic growth factors involved in monocytopoiesis, interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) were studied for their ability to stimulate blood monocytes and to bind to the monocyte membrane. Both cytokines maintained monocyte/macrophage numbers during long-term culture and increased cell size as compared with controls. Effects on cell numbers were present at low cytokine concentrations (6 to 20 pmol/L), whereas enhanced 3H-thymidine incorporation was observed only at higher concentrations (greater than or equal to 60 pmol/L). Autoradiographic studies showed only 1% to 3% of stimulated monocytes with nuclear grains. These results suggest that the primary mechanism for IL-3 and GM-CSF-induced maintenance of monocyte/macrophage numbers in humans is through an effect on cell survival. Surface receptors for both IL-3 and GM-CSF were studied by using 125I-labeled recombinant human (rh) cytokines and performing Scatchard analyses. Both cytokines showed curvilinear Scatchard plots, and computer analyses favored a two-site binding model. High-affinity binding data for 125I rhIL-3 (Kd 7.7 to 38.2 pmol/L; receptor number/cell 95 to 580) and for 125I rhGM-CSF (Kd 4.7 to 38.9 pmol/L; receptor number/cell 8 to 67) show similar binding affinities for the two cytokines but a lower receptor number/cell for 125I rhGM-CSF. Low-affinity binding characteristics for 125I rhIL-3 (Kd 513 to 939 pmol/L; receptor number/cell 179 to 5,274) and for 125I rhGM-CSF (Kd 576 to 1,120 pmol/L; receptor number/cell 130 to 657) show a similar pattern for the two cytokines. Specificity of 125I rhIL-3 and 125I rhGM-CSF binding to monocytes was established by the ability of the homologous cytokine to inhibit binding and the inability of a range of other cytokines to compete at 100-fold excess molar concentration. It is important, however, that binding of 125I rhIL-3 was partially inhibited by rhGM-CSF and that rhIL-3 partially inhibited binding of 125I rhGM-CSF to the monocyte membrane under conditions shown to prevent receptor internalization. The degree of inhibition varied between 25% and 80% in different experiments, and quantitative inhibition experiments showed that 1,000-fold excess concentrations of competitor failed to inhibit binding of the heterologous ligand completely. These results demonstrate that human IL-3 and GM-CSF have similar effects on growth and survival of human monocytes in vitro and suggest that these and other common biological effects may be mediated either through a common receptor or through distinct receptors associated on the monocyte membrane.

Citing Articles

Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target.

Koni M, Castellano I, Venturelli E, Sarcinella A, Lopatina T, Grange C Cancers (Basel). 2022; 14(16).

PMID: 36010912 PMC: 9406043. DOI: 10.3390/cancers14163918.


CSF1R defines the mononuclear phagocyte system lineage in human blood in health and COVID-19.

Combes T, Orsenigo F, Stewart A, Mendis A, Dunn-Walters D, Gordon S Immunother Adv. 2022; 1(1):ltab003.

PMID: 35915730 PMC: 7928847. DOI: 10.1093/immadv/ltab003.


Role of Cytokines in Experimental and Human Visceral Leishmaniasis.

Samant M, Sahu U, Pandey S, Khare P Front Cell Infect Microbiol. 2021; 11:624009.

PMID: 33680991 PMC: 7930837. DOI: 10.3389/fcimb.2021.624009.


Directs effects of granulocyte-macrophage colony stimulating factor (GM-CSF) on adaptive immunogenesis.

Seledtsov V, Malashchenko V, Gazatova N, Meniailo M, Morozova E, Seledtsova G Hum Vaccin Immunother. 2019; 15(12):2903-2909.

PMID: 31063025 PMC: 6930084. DOI: 10.1080/21645515.2019.1614396.


Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.

Dayakar A, Chandrasekaran S, Kuchipudi S, Kalangi S Front Immunol. 2019; 10:670.

PMID: 31024534 PMC: 6459942. DOI: 10.3389/fimmu.2019.00670.